Inhibitory Effects of Anti-CA I Autoantibodies and Monoclonal Antibody mAb 2B8
Author Information
Author(s): Petra Chalova, Barbora Jankovicova, Veronika Dvorakova, Eliska Zelinkova, Zuzana Bilkova, Marcela Slovakova, Lucie Korecka, Petr Muller, Maksym Danchenko, Lenka Minichova, Jan Lakota, Ludovit Skultety
Primary Institution: Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
Hypothesis
Do anti-CA I antibodies ignite antitumor cascades after fusion with malignant cells, or is their focus largely on CA I molecules?
Conclusion
The study found that anti-CA I autoantibodies and the monoclonal antibody mAb 2B8 can significantly inhibit the esterase activity of carbonic anhydrase I.
Supporting Evidence
- Anti-CA I autoantibodies from multiple myeloma patients impact CA I esterase activity.
- The newly developed anti-CA I mAb 2B8 exhibits a similar inhibitory effect to patients' autoantibodies.
- The identified linear epitope for anti-CA I mAb 2B8 comprises the amino acid sequence DFWTYP.
Takeaway
This study shows that certain antibodies can stop a protein called carbonic anhydrase I from working, which might help fight cancer.
Methodology
The study involved isolating anti-CA I autoantibodies from patient serum and developing a monoclonal antibody, mAb 2B8, to assess its inhibitory effects on carbonic anhydrase I activity.
Limitations
The study primarily focuses on in vitro analyses, which may not fully represent in vivo conditions.
Participant Demographics
Patients with hemato-oncological malignancies were involved in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website